Investigational drug · Phase 2
HK-660S
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Primary Sclerosing Cholangitis (PSC).
Phase 2Last checked: Nov 19, 2026Latest source record: May 16, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "HK-660S"
First trial start
2025
Aug 18, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HK-660S", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary Sclerosing Cholangitis (PSC)
Approved drugs for the same conditions: Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "HK-660S" as an intervention, largest first.
- Efficacy and Safety of HK-660S in the Treatment of Primary Sclerosing CholangitisPivotal-lookingNot yet recruiting
CuromeBiosciencesIndustry
NCT06975150 · 105 participants (planned) · Start Aug 18, 2025 · Primary completion Aug 30, 2028
Drug: HK-660S 100mg; HK-660S 200mg and 1 more · For: Primary Sclerosing Cholangitis (PSC)
- Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing CholangitisCompleted
CuromeBiosciencesIndustry
NCT05866809 · 23 participants · Start Oct 28, 2021 · Primary completion Jun 23, 2023
Drug: HK-660S; Placebo · For: Primary Sclerosing Cholangitis
Sites: Seoul, South Korea · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Correspondence to letter to the editor on "Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial".
Paik WH, Jeong HS, Park DH · Clin Mol Hepatol 2026
- Letter to the editor on "Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial".
Jiang B, Zhang S, Bao L · Clin Mol Hepatol 2026
- Critical considerations in evaluating the therapeutic potential of HK-660S for primary sclerosing cholangitis: Letter to the editor on "Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: a randomized double-blind phase 2a trial".
He Y, He H, Liang Q, et al. · Clin Mol Hepatol 2026
- Correspondence to editorial on "Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial".
Paik WH, Park DH · Clin Mol Hepatol 2025
- A novel clinical trial for primary sclerosing cholangitis from Asia: All regional endeavors should improve global management of primary sclerosing cholangitis: Editorial on "Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial".
Komori A · Clin Mol Hepatol 2025
- Challenges and innovations in primary sclerosing cholangitis clinical trials: Evaluating HK-660S and the path forward: Editorial on "Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial".
Nishad N · Clin Mol Hepatol 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.